Min-Hee Ryu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Min-Hee Ryu has a total of 401 co-authors. Here are the top co-authors by number of shared publications:
- Yung-Jue Bang
Seoul National University College of Medicine, Seoul, South Korea
42 shared publications - Anas Gazzah
Département d'Innovation Thérapeutique et d'Essais Précoces (DITEP), Gustave Roussy, Villejuif, France
40 shared publications - Christine Soufflet
Clinical Development, Sanofi, Vitry-Sur-Seine, France
40 shared publications - Josep Tabernero
Medical Oncology Department, Vall d’Hebron University Hospital, Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain
40 shared publications - Maria Vieito
Hospital Universitari Vall d'Hebron, Barcelona, Spain
40 shared publications - Mustapha Chadjaa
Sanofi, Paris, France
40 shared publications
Latest Publications
- 21 October 2026
- Published by Springer Nature in Gastric Cancer
- Vol. 29 (6) , 1258-1267
Clinical outcomes and germline implications of primary KIT exon 13 and 17 mutations in gastrointestinal stromal tumors
- 21 October 2026
- Published by Springer Nature in Gastric Cancer
- Vol. 29 (6) , 1258-1267
Clinical outcomes and germline implications of primary KIT exon 13 and 17 mutations in gastrointestinal stromal tumors
- Open Access
- 7 September 2026
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 14 (9) , e014309
Phase 1/1b open-label, first-in-human study of HER2×CD3×CD28 trispecific T-cell engager (SAR443216) in participants with R/R HER2-expressing solid tumors
Background: SAR443216 is an engineered human trispecific antibody that targets human epidermal growth factor receptor 2 (HER2)-positive (HER2+) cancer cells and activates T cells via co-engagement of cluster of differentiation (CD)3 and CD28. This first-in-human, dose-escalation study evaluated the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics of SAR443216 in participants with relapsed/refractory (R/R) HER2-expressing solid tumors. Methods: In this multicenter, open-label, non-randomized Phase 1 study ( NCT05013554 ), SAR443216 was administered intravenously at dose levels (DLs) of 18–900 µg. Dose escalation occurred within participants using intraparticipant lead-in dosing (2-week and 3-week lead-in cohorts). The primary objective was to determine the maximum tolerated dose (MTD); secondary objectives included PK, immunogenicity, and preliminary clinical activity. Results: 40 participants (n≥3 at each DL) were treated with SAR443216. The median treatment duration was ~8 weeks in both 2-week and 3-week lead-in cohorts. Nearly all participants (97.5%) had at least one treatment-emergent adverse event (TEAE), of which 45% were grade ≥3. Most frequent TEAEs were cytokine release syndrome (CRS, 50%), fever (35%), alanine aminotransferase elevation (32.5%), aspartate aminotransferase elevation (27.5%), and infusion-related reactions (IRRs, 27.5%). No severe CRS, IRRs, fever, or pulmonary and cardiac toxicities were observed. Disease control rates were 34.5% in the 2-week and 36.4% in the 3-week lead-in cohorts. Average duration of disease stabilization was 10.48 weeks. Median follow-up time was 3.43 weeks. No objective responses were observed. The MTD was not reached. Dose-dependent PK showed overall consistent PK profiles across DLs. SAR443216 induced serum proinflammatory cytokines and increased multiple T-cell activation markers in peripheral blood mononuclear cells, indicating T-cell activation and target engagement. However, no clear trend in T-cell abundance or activation was observed among tumor-infiltrating T cells or other immune cells. Conclusion: These findings indicate that SAR443216 treatment is feasible and well tolerated in participants with R/R HER2+solid tumors. Further evaluation is warranted to fully characterize the efficacy and safety of SAR443216. Trial registration number: NCT05013554 .
- 7 September 2026
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 14 (9) , e014309
Open AccessPhase 1/1b open-label, first-in-human study of HER2×CD3×CD28 trispecific T-cell engager (SAR443216) in participants with R/R HER2-expressing solid tumors
Background: SAR443216 is an engineered human trispecific antibody that targets human epidermal growth factor receptor 2 (HER2)-positive (HER2+) cancer cells and activates T cells via co-engagement of cluster of differentiation (CD)3 and CD28. This first-in-human, dose-escalation study evaluated the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics of SAR443216 in participants with relapsed/refractory (R/R) HER2-expressing solid tumors. Methods: In this multicenter, open-label, non-randomized Phase 1 study ( NCT05013554 ), SAR443216 was administered intravenously at dose levels (DLs) of 18–900 µg. Dose escalation occurred within participants using intraparticipant lead-in dosing (2-week and 3-week lead-in cohorts). The primary objective was to determine the maximum tolerated dose (MTD); secondary objectives included PK, immunogenicity, and preliminary clinical activity. Results: 40 participants (n≥3 at each DL) were treated with SAR443216. The median treatment duration was ~8 weeks in both 2-week and 3-week lead-in cohorts. Nearly all participants (97.5%) had at least one treatment-emergent adverse event (TEAE), of which 45% were grade ≥3. Most frequent TEAEs were cytokine release syndrome (CRS, 50%), fever (35%), alanine aminotransferase elevation (32.5%), aspartate aminotransferase elevation (27.5%), and infusion-related reactions (IRRs, 27.5%). No severe CRS, IRRs, fever, or pulmonary and cardiac toxicities were observed. Disease control rates were 34.5% in the 2-week and 36.4% in the 3-week lead-in cohorts. Average duration of disease stabilization was 10.48 weeks. Median follow-up time was 3.43 weeks. No objective responses were observed. The MTD was not reached. Dose-dependent PK showed overall consistent PK profiles across DLs. SAR443216 induced serum proinflammatory cytokines and increased multiple T-cell activation markers in peripheral blood mononuclear cells, indicating T-cell activation and target engagement. However, no clear trend in T-cell abundance or activation was observed among tumor-infiltrating T cells or other immune cells. Conclusion: These findings indicate that SAR443216 treatment is feasible and well tolerated in participants with R/R HER2+solid tumors. Further evaluation is warranted to fully characterize the efficacy and safety of SAR443216. Trial registration number: NCT05013554 .
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Data1 from A Phase Ib/IIa Study of Fostrox in Combination with Lenvatinib as Second-line Therapy in Patients with Advanced Hepatocellular Carcinoma
Contents: Figure S1. Longitudinal measure of ALT, AST,total bilirubin levels, and ALBI score. Figure S2. Longitudinal measure of neutrophil levels and thrombocyte levels Figure S3. Dose reduction and discontinuation due to adverse events Figure S4. Pharmacokinetics; plasma concentrations for fostrox and troxacitabine Figure S5. Liver biopsy PD marker expression Table S1. Exposure to fostrox and troxacitabine in plasma after one cycle of fostrox administration Table S2. Representativeness of Study Participants
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data1 from A Phase Ib/IIa Study of Fostrox in Combination with Lenvatinib as Second-line Therapy in Patients with Advanced Hepatocellular Carcinoma
Contents: Figure S1. Longitudinal measure of ALT, AST,total bilirubin levels, and ALBI score. Figure S2. Longitudinal measure of neutrophil levels and thrombocyte levels Figure S3. Dose reduction and discontinuation due to adverse events Figure S4. Pharmacokinetics; plasma concentrations for fostrox and troxacitabine Figure S5. Liver biopsy PD marker expression Table S1. Exposure to fostrox and troxacitabine in plasma after one cycle of fostrox administration Table S2. Representativeness of Study Participants
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Data from A Phase Ib/IIa Study of Fostrox in Combination with Lenvatinib as Second-line Therapy in Patients with Advanced Hepatocellular Carcinoma
Purpose:Immunotherapy has significantly improved outcomes in advanced hepatocellular carcinoma (HCC). However, most patients eventually progress, and second-line (2L) options remain limited. Fostroxacitabine bralpamide (fostrox), a liver-targeted prodrug, was administered in combination with lenvatinib, aiming at enhancing antitumor activity while avoiding further deterioration of residual liver function. Patients and Methods:This multicenter, single-arm phase Ib/IIa study evaluated the safety, pharmacokinetics (PK)/pharmacodynamics, and efficacy of fostrox (orally for 5 days in 21-day cycles), plus lenvatinib (standard doses), in locally advanced unresectable or metastatic HCC progressed on first-line/2L therapy (NCT03781934). A 3 + 3 dose-escalation design was used to determine the recommended phase II dose (RP2D). Results:Twenty-one patients were enrolled, and the median follow-up was 10.5 months. No dose-limiting toxicities were observed, and the RP2D of fostrox was established at 30 mg. All patients reported adverse events (AE), with 81% being grade ≥3 with possible relation to fostrox in 52.5% and to lenvatinib in 66.7% of cases. Fostrox-related AEs were mainly transient neutropenia and thrombocytopenia. Other AEs, mainly attributed to lenvatinib, were grade I/II and consistent with monotherapy use. Fostrox dose reduction and discontinuation rates were 29% and 5%, and for lenvatinib the rates were 52% and 14%, respectively. There were no signs of treatment-related liver function deterioration. The overall response rate was 24%, disease control rate was 81%, median time to progression was 10.9 months, median progression-free survival was 6.7 months, and median overall survival was 13.7 months. Fostrox PK analyses confirmed dose proportionality, and liver biopsies showed tumor-selective DNA damage. Conclusions:The combination of fostrox and lenvatinib demonstrated promising preliminary efficacy and tolerability after immunotherapy, supporting further investigation as a 2L option in advanced HCC.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from A Phase Ib/IIa Study of Fostrox in Combination with Lenvatinib as Second-line Therapy in Patients with Advanced Hepatocellular Carcinoma
Purpose:Immunotherapy has significantly improved outcomes in advanced hepatocellular carcinoma (HCC). However, most patients eventually progress, and second-line (2L) options remain limited. Fostroxacitabine bralpamide (fostrox), a liver-targeted prodrug, was administered in combination with lenvatinib, aiming at enhancing antitumor activity while avoiding further deterioration of residual liver function. Patients and Methods:This multicenter, single-arm phase Ib/IIa study evaluated the safety, pharmacokinetics (PK)/pharmacodynamics, and efficacy of fostrox (orally for 5 days in 21-day cycles), plus lenvatinib (standard doses), in locally advanced unresectable or metastatic HCC progressed on first-line/2L therapy (NCT03781934). A 3 + 3 dose-escalation design was used to determine the recommended phase II dose (RP2D). Results:Twenty-one patients were enrolled, and the median follow-up was 10.5 months. No dose-limiting toxicities were observed, and the RP2D of fostrox was established at 30 mg. All patients reported adverse events (AE), with 81% being grade ≥3 with possible relation to fostrox in 52.5% and to lenvatinib in 66.7% of cases. Fostrox-related AEs were mainly transient neutropenia and thrombocytopenia. Other AEs, mainly attributed to lenvatinib, were grade I/II and consistent with monotherapy use. Fostrox dose reduction and discontinuation rates were 29% and 5%, and for lenvatinib the rates were 52% and 14%, respectively. There were no signs of treatment-related liver function deterioration. The overall response rate was 24%, disease control rate was 81%, median time to progression was 10.9 months, median progression-free survival was 6.7 months, and median overall survival was 13.7 months. Fostrox PK analyses confirmed dose proportionality, and liver biopsies showed tumor-selective DNA damage. Conclusions:The combination of fostrox and lenvatinib demonstrated promising preliminary efficacy and tolerability after immunotherapy, supporting further investigation as a 2L option in advanced HCC.
- Open Access
- 26 June 2026
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 31 (8)
Phase IB/II study of alpelisib combined with paclitaxel in patients with PIK3CA-altered metastatic or recurrent gastric cancer.
This phase IB/II study assessed safety, pharmacokinetics, and efficacy of alpelisib, a selective PI3Kα inhibitor, plus weekly paclitaxel in patients with PIK3CA-altered metastatic or recurrent gastric cancer (GC). In phase IB, patients with advanced solid tumors received alpelisib 250 mg (dose level [DL] 0) or 300 mg (DL1) once daily plus paclitaxel 70 mg/m2 on days 1, 8, and 15 every 4 weeks to determine maximum tolerated dose (MTD), dose-limiting toxicity (DLT), and the recommended phase II dose (RP2D). In phase II, patients with PIK3CA-altered GC received RP2D, and the primary endpoint was 4-month progression-free survival (PFS). Subjects with diabetes or those with risk factors for diabetes who also had impaired glucose tolerance were excluded. Pharmacokinetic sampling was performed in phase IB at cycle 1, days 1 (initial dose) and 8 (steady state). In phase IB, MTD was not reached; RP2D was established at DL1. Two patients developed DLTs at DL0 (grade 3 hyperglycemia, diarrhea, and fatigue) and DL1 (grade 3 hyponatremia). Toxicities were consistent with known PI3Kα inhibitor plus taxane combination profiles and were generally manageable. In phase II (n = 9), the 4-month PFS rate was 22.2%, and enrollment was discontinued early for futility; no objective responses were observed, and the median PFS was 2.6 months. Alpelisib exposure, assessed by Cmax and AUC0-24, was within expected ranges, and prior gastrectomy was associated with lower exposure. Alpelisib plus paclitaxel was tolerable and pharmacologically feasible with a defined RP2D but showed limited efficacy in PIK3CA-altered GC.
- 26 June 2026
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 31 (8)
Open AccessPhase IB/II study of alpelisib combined with paclitaxel in patients with PIK3CA-altered metastatic or recurrent gastric cancer.
This phase IB/II study assessed safety, pharmacokinetics, and efficacy of alpelisib, a selective PI3Kα inhibitor, plus weekly paclitaxel in patients with PIK3CA-altered metastatic or recurrent gastric cancer (GC). In phase IB, patients with advanced solid tumors received alpelisib 250 mg (dose level [DL] 0) or 300 mg (DL1) once daily plus paclitaxel 70 mg/m2 on days 1, 8, and 15 every 4 weeks to determine maximum tolerated dose (MTD), dose-limiting toxicity (DLT), and the recommended phase II dose (RP2D). In phase II, patients with PIK3CA-altered GC received RP2D, and the primary endpoint was 4-month progression-free survival (PFS). Subjects with diabetes or those with risk factors for diabetes who also had impaired glucose tolerance were excluded. Pharmacokinetic sampling was performed in phase IB at cycle 1, days 1 (initial dose) and 8 (steady state). In phase IB, MTD was not reached; RP2D was established at DL1. Two patients developed DLTs at DL0 (grade 3 hyperglycemia, diarrhea, and fatigue) and DL1 (grade 3 hyponatremia). Toxicities were consistent with known PI3Kα inhibitor plus taxane combination profiles and were generally manageable. In phase II (n = 9), the 4-month PFS rate was 22.2%, and enrollment was discontinued early for futility; no objective responses were observed, and the median PFS was 2.6 months. Alpelisib exposure, assessed by Cmax and AUC0-24, was within expected ranges, and prior gastrectomy was associated with lower exposure. Alpelisib plus paclitaxel was tolerable and pharmacologically feasible with a defined RP2D but showed limited efficacy in PIK3CA-altered GC.
- Open Access
- 23 June 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (17) , OF1-OF10
A Phase Ib/IIa Study of Fostrox in Combination with Lenvatinib as Second-line Therapy in Patients with Advanced Hepatocellular Carcinoma
Purpose: Immunotherapy has significantly improved outcomes in advanced hepatocellular carcinoma (HCC). However, most patients eventually progress, and second-line (2L) options remain limited. Fostroxacitabine bralpamide (fostrox), a liver-targeted prodrug, was administered in combination with lenvatinib, aiming at enhancing antitumor activity while avoiding further deterioration of residual liver function. Patients and Methods: This multicenter, single-arm phase Ib/IIa study evaluated the safety, pharmacokinetics (PK)/pharmacodynamics, and efficacy of fostrox (orally for 5 days in 21-day cycles), plus lenvatinib (standard doses), in locally advanced unresectable or metastatic HCC progressed on first-line/2L therapy (NCT03781934). A 3 + 3 dose-escalation design was used to determine the recommended phase II dose (RP2D). Results: Twenty-one patients were enrolled, and the median follow-up was 10.5 months. No dose-limiting toxicities were observed, and the RP2D of fostrox was established at 30 mg. All patients reported adverse events (AE), with 81% being grade ≥3 with possible relation to fostrox in 52.5% and to lenvatinib in 66.7% of cases. Fostrox-related AEs were mainly transient neutropenia and thrombocytopenia. Other AEs, mainly attributed to lenvatinib, were grade I/II and consistent with monotherapy use. Fostrox dose reduction and discontinuation rates were 29% and 5%, and for lenvatinib the rates were 52% and 14%, respectively. There were no signs of treatment-related liver function deterioration. The overall response rate was 24%, disease control rate was 81%, median time to progression was 10.9 months, median progression-free survival was 6.7 months, and median overall survival was 13.7 months. Fostrox PK analyses confirmed dose proportionality, and liver biopsies showed tumor-selective DNA damage. Conclusions: The combination of fostrox and lenvatinib demonstrated promising preliminary efficacy and tolerability after immunotherapy, supporting further investigation as a 2L option in advanced HCC.
- 23 June 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (17) , OF1-OF10
Open AccessA Phase Ib/IIa Study of Fostrox in Combination with Lenvatinib as Second-line Therapy in Patients with Advanced Hepatocellular Carcinoma
Purpose: Immunotherapy has significantly improved outcomes in advanced hepatocellular carcinoma (HCC). However, most patients eventually progress, and second-line (2L) options remain limited. Fostroxacitabine bralpamide (fostrox), a liver-targeted prodrug, was administered in combination with lenvatinib, aiming at enhancing antitumor activity while avoiding further deterioration of residual liver function. Patients and Methods: This multicenter, single-arm phase Ib/IIa study evaluated the safety, pharmacokinetics (PK)/pharmacodynamics, and efficacy of fostrox (orally for 5 days in 21-day cycles), plus lenvatinib (standard doses), in locally advanced unresectable or metastatic HCC progressed on first-line/2L therapy (NCT03781934). A 3 + 3 dose-escalation design was used to determine the recommended phase II dose (RP2D). Results: Twenty-one patients were enrolled, and the median follow-up was 10.5 months. No dose-limiting toxicities were observed, and the RP2D of fostrox was established at 30 mg. All patients reported adverse events (AE), with 81% being grade ≥3 with possible relation to fostrox in 52.5% and to lenvatinib in 66.7% of cases. Fostrox-related AEs were mainly transient neutropenia and thrombocytopenia. Other AEs, mainly attributed to lenvatinib, were grade I/II and consistent with monotherapy use. Fostrox dose reduction and discontinuation rates were 29% and 5%, and for lenvatinib the rates were 52% and 14%, respectively. There were no signs of treatment-related liver function deterioration. The overall response rate was 24%, disease control rate was 81%, median time to progression was 10.9 months, median progression-free survival was 6.7 months, and median overall survival was 13.7 months. Fostrox PK analyses confirmed dose proportionality, and liver biopsies showed tumor-selective DNA damage. Conclusions: The combination of fostrox and lenvatinib demonstrated promising preliminary efficacy and tolerability after immunotherapy, supporting further investigation as a 2L option in advanced HCC.
- 1 June 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
EP4 Antagonist ONO-4578 Plus Nivolumab and Chemotherapy in HER2-Negative Unresectable Advanced or Recurrent Gastric or Gastroesophageal Junction Cancer
Purpose: EP4, a key receptor in the PGE 2 axis, mediates tumor immunosuppression; the EP4 antagonist ONO-4578 plus nivolumab showed manageable safety, immune activation, and preliminary antitumor activity in previously treated gastric/gastroesophageal junction cancer (G/GEJC). This study explored whether ONO-4578 enhances the efficacy of nivolumab plus chemotherapy in unresectable advanced or recurrent G/GEJC. Patients and Methods: This multicenter, double-blind, randomized phase 2 study enrolled chemotherapy-naïve patients with HER2-negative unresectable advanced or recurrent G/GEJC. Patients were randomized (2:1) to receive oral ONO-4578 or matching placebo, each in combination with nivolumab and oxaliplatin-based chemotherapy. The primary endpoint was investigator-assessed progression-free survival (PFS). Secondary endpoints included overall survival (OS), objective response rate (ORR), and safety. Results: At the data cutoff, 226 patients were randomized to the ONO-4578 group (n = 150) and the placebo group (n = 76). Adding ONO-4578 significantly improved PFS (hazard ratio of 0.67; 90% confidence interval, 0.48–0.92; p-value, 0.040 [prespecified two-sided α = 0.10]), with favorable OS at a prespecified analysis with limited follow-up (hazard ratio of 0.60; 95% confidence interval, 0.37–0.96) and ORR (62.0% vs 48.7%). Exploratory subgroup analyses suggested that ONO-4578 regimen provided greater benefit in PD-L1 CPS ≥1, whereas no clear benefit in CPS <1/indeterminate patients. In an extended follow-up exploratory OS analysis with a minimum follow-up of 16.1 months, OS numerically favored ONO-4578 regimen. Common treatment-emergent adverse events in the ONO-4578 group were diarrhoea (55.7% vs 45.3%), and anaemia (55.0% vs 34.7%). Conclusion: This study demonstrated promising efficacy and acceptable safety of an ONO-4578 regimen as first-line treatment for HER2-negative unresectable advanced or recurrent G/GEJC. These findings warrant confirmation in a phase 3 trial.
- 1 June 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
EP4 Antagonist ONO-4578 Plus Nivolumab and Chemotherapy in HER2-Negative Unresectable Advanced or Recurrent Gastric or Gastroesophageal Junction Cancer
Purpose: EP4, a key receptor in the PGE 2 axis, mediates tumor immunosuppression; the EP4 antagonist ONO-4578 plus nivolumab showed manageable safety, immune activation, and preliminary antitumor activity in previously treated gastric/gastroesophageal junction cancer (G/GEJC). This study explored whether ONO-4578 enhances the efficacy of nivolumab plus chemotherapy in unresectable advanced or recurrent G/GEJC. Patients and Methods: This multicenter, double-blind, randomized phase 2 study enrolled chemotherapy-naïve patients with HER2-negative unresectable advanced or recurrent G/GEJC. Patients were randomized (2:1) to receive oral ONO-4578 or matching placebo, each in combination with nivolumab and oxaliplatin-based chemotherapy. The primary endpoint was investigator-assessed progression-free survival (PFS). Secondary endpoints included overall survival (OS), objective response rate (ORR), and safety. Results: At the data cutoff, 226 patients were randomized to the ONO-4578 group (n = 150) and the placebo group (n = 76). Adding ONO-4578 significantly improved PFS (hazard ratio of 0.67; 90% confidence interval, 0.48–0.92; p-value, 0.040 [prespecified two-sided α = 0.10]), with favorable OS at a prespecified analysis with limited follow-up (hazard ratio of 0.60; 95% confidence interval, 0.37–0.96) and ORR (62.0% vs 48.7%). Exploratory subgroup analyses suggested that ONO-4578 regimen provided greater benefit in PD-L1 CPS ≥1, whereas no clear benefit in CPS <1/indeterminate patients. In an extended follow-up exploratory OS analysis with a minimum follow-up of 16.1 months, OS numerically favored ONO-4578 regimen. Common treatment-emergent adverse events in the ONO-4578 group were diarrhoea (55.7% vs 45.3%), and anaemia (55.0% vs 34.7%). Conclusion: This study demonstrated promising efficacy and acceptable safety of an ONO-4578 regimen as first-line treatment for HER2-negative unresectable advanced or recurrent G/GEJC. These findings warrant confirmation in a phase 3 trial.
- 28 January 2026
- Published by Wiley in International Journal of Cancer
- Vol. 158 (11) , 2947-2956
Association between the presence of malignant ascites and survival outcomes in gastric cancer patients treated with nivolumab plus chemotherapy
Although malignant ascites is associated with poor outcomes in gastric cancer (GC), its clinical value in first‐line immune checkpoint inhibitor (ICI)‐based chemotherapy remains unclear. This single‐center study aimed to evaluate the impact of malignant ascites in patients with advanced GC treated with first‐line nivolumab plus chemotherapy ( n = 339) or chemotherapy alone ( n = 422). Peritoneal involvement and malignant ascites grade were assessed using computed tomography imaging. Patients were classified into no peritoneal metastases (PM), PM without ascites, and PM with ascites groups. In the nivolumab plus chemotherapy group, patients with PM and ascites exhibited significantly worse survival (median PFS: 5.1 months; OS: 11.6 months) than those with no PM (median PFS: 10.2 months; OS: 22.0 months) or PM without ascites (median PFS: 10.8 months; OS: 19.7 months) ( p < 0.001). While nivolumab plus chemotherapy was evidently associated with favorable survival outcomes for patients without malignant ascites compared to chemotherapy (PFS: p < 0.001; OS: p = 0.01), such survival benefits were not observed in those with PM and ascites (PFS: p = 0.09; OS: p = 0.39). This trend persisted in the PD‐L1 combined positive score ≥5 and deficient mismatch repair subgroups. Our results reveal that malignant ascites is associated with poor survival with nivolumab plus chemotherapy, and limited benefit from adding nivolumab to chemotherapy in patients with GC. We suggest that malignant ascites may be considered a stratification factor in future clinical trials of ICI‐based treatments for GC.
- 28 January 2026
- Published by Wiley in International Journal of Cancer
- Vol. 158 (11) , 2947-2956
Association between the presence of malignant ascites and survival outcomes in gastric cancer patients treated with nivolumab plus chemotherapy
Although malignant ascites is associated with poor outcomes in gastric cancer (GC), its clinical value in first‐line immune checkpoint inhibitor (ICI)‐based chemotherapy remains unclear. This single‐center study aimed to evaluate the impact of malignant ascites in patients with advanced GC treated with first‐line nivolumab plus chemotherapy ( n = 339) or chemotherapy alone ( n = 422). Peritoneal involvement and malignant ascites grade were assessed using computed tomography imaging. Patients were classified into no peritoneal metastases (PM), PM without ascites, and PM with ascites groups. In the nivolumab plus chemotherapy group, patients with PM and ascites exhibited significantly worse survival (median PFS: 5.1 months; OS: 11.6 months) than those with no PM (median PFS: 10.2 months; OS: 22.0 months) or PM without ascites (median PFS: 10.8 months; OS: 19.7 months) ( p < 0.001). While nivolumab plus chemotherapy was evidently associated with favorable survival outcomes for patients without malignant ascites compared to chemotherapy (PFS: p < 0.001; OS: p = 0.01), such survival benefits were not observed in those with PM and ascites (PFS: p = 0.09; OS: p = 0.39). This trend persisted in the PD‐L1 combined positive score ≥5 and deficient mismatch repair subgroups. Our results reveal that malignant ascites is associated with poor survival with nivolumab plus chemotherapy, and limited benefit from adding nivolumab to chemotherapy in patients with GC. We suggest that malignant ascites may be considered a stratification factor in future clinical trials of ICI‐based treatments for GC.